Shares of Neos Therapeutics Inc. (NASDAQ:NEOS) traded down 6.6% on Monday . The company traded as low as $7.77 and last traded at $7.80, with a volume of 77,735 shares changing hands. The stock had previously closed at $8.35.
Separately, BMO Capital Markets assumed coverage on shares of Neos Therapeutics in a report on Tuesday, June 28th. They issued an “outperform” rating and a $15.00 price target for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Neos Therapeutics presently has an average rating of “Buy” and an average target price of $21.75.
The firm’s market capitalization is $121.33 million. The company has a 50 day moving average price of $7.70 and a 200-day moving average price of $9.20.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/neos-therapeutics-inc-neos-shares-down-6-6.html
Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.16) by $0.49. Neos Therapeutics had a negative net margin of 968.81% and a negative return on equity of 80.10%. The business earned $1.49 million during the quarter, compared to analyst estimates of $1.48 million. On average, equities research analysts forecast that Neos Therapeutics Inc. will post ($5.38) earnings per share for the current fiscal year.
In other Neos Therapeutics news, CFO Richard I. Eisenstadt purchased 3,710 shares of the firm’s stock in a transaction on Thursday, August 25th. The stock was purchased at an average cost of $6.82 per share, for a total transaction of $25,302.20. Following the transaction, the chief financial officer now owns 3,710 shares in the company, valued at approximately $25,302.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.85% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in NEOS. ProShare Advisors LLC boosted its position in shares of Neos Therapeutics by 10.0% in the second quarter. ProShare Advisors LLC now owns 13,622 shares of the company’s stock valued at $126,000 after buying an additional 1,233 shares during the period. Schwab Charles Investment Management Inc. acquired a new position in shares of Neos Therapeutics during the second quarter valued at about $200,000. Teachers Advisors Inc. boosted its position in shares of Neos Therapeutics by 289.6% in the second quarter. Teachers Advisors Inc. now owns 21,924 shares of the company’s stock valued at $203,000 after buying an additional 16,296 shares during the period. California State Teachers Retirement System boosted its position in shares of Neos Therapeutics by 140.1% in the second quarter. California State Teachers Retirement System now owns 28,815 shares of the company’s stock valued at $267,000 after buying an additional 16,815 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Neos Therapeutics by 73.1% in the second quarter. Bank of New York Mellon Corp now owns 38,008 shares of the company’s stock valued at $353,000 after buying an additional 16,046 shares during the period. Hedge funds and other institutional investors own 37.73% of the company’s stock.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.